Recent cancer research has revealed an unexpected potential for vitamin K precursors, particularly menadione (vitamin K3), in treating cancer. Unlike antioxidants that protect cells from damage, menadione functions as a pro-oxidant, promoting oxidation processes that generate reactive oxygen species (ROS). These ROS can be harnessed to selectively target and destroy cancer cells without harming healthy tissue. A study led by Lloyd Trotman at Cold Spring Harbor Laboratory demonstrated that menadione induces oxidative stress in cancer cells, disrupting their survival mechanisms and leading to cell death. This discovery suggests a new approach to cancer treatment, using menadione’s unique properties to develop more effective and targeted therapies, marking a shift in how we understand and fight cancer.